Collaboration brings together two Australian companies in scaling access to oncology therapies

Pharma News: Two oncology focussed organisations have announced a new strategic collaboration to benefit Australians living with complex, hard-to-treat cancers. The partnership will see Radiopharm Theranostics and GenesisCare conduct several world-first Phase 1 clinical trials in Australia, focusing on areas of high-unmet need in oncology.

Radiopharmaceuticals are designed to enrich the current pillars of cancer treatment by complementing surgery, postponing the need for chemotherapy and enhancing efficacy of targeted and immunotherapies.

As part of the collaboration, GenesisCare’s Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), has already been awarded contracts to implement three Phase 1 clinical trials in Australia, involving Radiopharm’s platform of radiopharmaceutical nanobodies.

To date, the majority of clinical developments in radiopharmaceuticals have targeted metastatic prostate cancer and neuroendocrine tumours.

Radiopharm’s Chief Executive Officer & Managing Director, Riccardo Canevari, said “Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options.

“We are delighted to be extending and strengthening our partnership with GenesisCare, a world-leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”

GenesisCare’s Chief Scientific Officer, Research & Insights, Dr Danielle Meyrick, PhD, said “GenesisCare’s CRO is a world leading provider of clinical, imaging, and dosimetric services for the development of novel radiopharmaceuticals for both diagnostic and therapeutic purposes.

“We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia. Together we hope to unlock and realise the full potential of Theranostics as a key pillar of modern cancer therapy.

This R&D collaboration brings together two Australian-founded healthcare companies, who share the same commitment to investing and developing new therapies in Australia, and scaling patient access to these innovations in a faster and more affordable way,” concluded Dr Meyrick.

Radiopharm’s research pipeline includes three key trials.

1.      Phase 1 trial involving Radiopharm’s proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer

2.     Phase 1 trial involving Radiopharm’s PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells

3.     Phase 1 trial involving Radiopharm’s Dunp-19 antibody targeting LRRC15 expression in osteosarcoma

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.